Aglatimagene besadenovec

Drug Profile

Aglatimagene besadenovec

Alternative Names: Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy; AdV-Tk; AdV-tk therapy - Advantagene; ADV/HSV-tk; Cancer gene therapy - Advantagene; Gene Mediated Cytotoxic Immunotherapy; GliAtak; HSV-vectored thymidine kinase; PancAtak; ProstAtak; TKR therapy - Advantagene

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator Advantagene
  • Developer Advantagene; Methodist Healthcare Ministries of South Texas
  • Class Antineoplastics; Gene therapies; Gene-directed enzyme-prodrug therapies
  • Mechanism of Action Thymidine kinase expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Prostate cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Prostate cancer
  • Phase II Glioma; Pancreatic cancer
  • Phase I/II Malignant pleural effusion; Ovarian cancer
  • Preclinical Glioblastoma; Mesothelioma; Oesophageal cancer

Most Recent Events

  • 22 Dec 2016 The Methodist Hospital System plans a phase II trial in Breast cancer and Non-small cell lung cancer in USA (NCT03004183)
  • 07 Sep 2016 Phase-II clinical trials in Pancreatic cancer in USA (Intratumoural) before September 2016
  • 01 Aug 2016 Advantagene completes a phase IIa trial for Glioma in USA (NCT00589875)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top